Needham analyst Mike Matson reiterates Haemonetics (NYSE:HAE) with a Buy and maintains $112 price target.
- Headlines
- Needham Reiterates Buy on Haemonetics, Maintains $112 Price Target
Needham Reiterates Buy on Haemonetics, Maintains $112 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
01:38
White House: Republicans need to adhere to the bipartisan agreement to keep the government open.
01:36
General Dynamics Corporation: General Dynamics Information Technology has been awarded a contract worth $5.6 billion by the Air Force Task Partner Capability Office.
GD+2.18%
01:33
Volkswagen will reorganize the production of its various factories.